期刊
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
卷 34, 期 2, 页码 147-160出版社
WILEY
DOI: 10.1111/j.1365-2710.2008.00978.x
关键词
chemokine receptor 5; chemokine receptor 5 antagonists; chemokine receptors; chemokines; entry inhibitors; fusion inhibitors; human immunodeficiency virus/acquired immune deficiency syndrome; maraviroc; vicriviroc
Since the recognition of human acquired immune deficiency syndrome, numerous classes of pharmacologic therapeutics have been developed to manage the disease. Current therapy includes co-administration of combinations of drugs classified by their mechanism of action as 'transcriptase inhibitors', 'protease inhibitors', 'integrase inhibitors' and the more recent 'fusion inhibitors'. This review focuses on the chemokine system and the recognition of chemokine receptors as targets for anti-human immunodeficiency virus (HIV) therapy. The FDA-approved chemokine (C-C motif) receptor 5 (CCR5) antagonist maraviroc (Selzentry(R)) is discussed in detail, along with another compound vicriviroc, currently in clinical trials. The mechanism of action, pharmacokinetics, toxicity and current status of research on CCR5 antagonists is described. Further, potential therapeutic uses of these agents other than anti-HIV therapy are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据